Incidence Rates and Frequency of Instrumental and Drug Treatments in Hospitalized Patients with Covid-19 And St-Segment Elevation Myocardial Infarction (Stemi)
EM Evsikov*, NV Teplova , KI Bairova , AG Dzheksembekov , AGVardanyan and Chobanjan MA
ABSTRACT
By E.M. Evsikov et al. “Incidence rates and frequency of instrumental and drug treatments in hospitalized patients with COVID-19 and ST-segment elevation myocardial infarction (STEMI)” Relevance of the topic
Policy reviews on this issue have noted that acute myocardial injury with elevated cardiac troponin (cTn) levels is associated with worse outcomes in patients with SARS-CoV-2 infections. In meta-analyses, the cumulative prevalence of acute myocardial injury according to diagnostic biochemical markers of myocardial damage varied in patients with covid-19 from 5% to 38%, depending on the criteria used, and exceeded an average of 20%.
Goal of the work: To study the features of providing medical care and conducting instrumental and drug treatment for patients COVID-19 hospitalized with acute coronary syndrome and myocardial infarction (AMI). To assess how the COVID-19 pandemic has impacted systems of care for patients with UTI and timely access to reperfusion therapy in different regions of the world. To determine the significance of the leading mechanisms of myocardial damage during COVID-19, such as hypercoagulation and the development of coronary microvascular thrombosis; diffuse endothelial damage and “endotheliitis” in multiple organs including the heart, inflammation and/or stress causing coronary plaque rupture or supply and demand imbalance leading to myocardial ischemia/infarction.
